US equities |
TSLA $391.62 ▲+5.21% MU $903.70 ▲+2.98% META $630.56 ▼-1.88% NVDA $216.00 ▲+2.39% AAPL $343.91 ▼-1.10% SPCX $146.90 ▼-0.40% MSFT $532.60 ▲+1.54% AMD $531.28 ▲+2.80%
FinancialContent

Amarin Corporation plc - American Depositary Shares (NQ:AMRN)

12.09 +0.30 (+2.54%)
Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amarin Corporation plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
Data Supports Approximately 30% Relative Risk Reduction Among Highly Adherent Patients and Provides Evidence Consistent with a Potential Legacy Effect in Secondary Prevention Patients After Treatment... 
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated Triglycerides 
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Reports 2026 First Quarter Financial Results
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
News headline image
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
U.S. IPE Market Leadership Sustained; $70M Restructuring OPEX Savings on Pace for Mid-2026; Completed Transition to Fully Partnered Model Across All International Markets 
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Reports Third Quarter 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action -- 
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Reports Second Quarter 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025
From Amarin Corporation plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >